CR20240344A - Inhibidores de apol1 y métodos de uso - Google Patents

Inhibidores de apol1 y métodos de uso

Info

Publication number
CR20240344A
CR20240344A CR20240344A CR20240344A CR20240344A CR 20240344 A CR20240344 A CR 20240344A CR 20240344 A CR20240344 A CR 20240344A CR 20240344 A CR20240344 A CR 20240344A CR 20240344 A CR20240344 A CR 20240344A
Authority
CR
Costa Rica
Prior art keywords
apol1
inhibitors
methods
yz8vxxx
yxfsleeps
Prior art date
Application number
CR20240344A
Other languages
English (en)
Inventor
Patrick Sang Tae Lee
Christopher Joseph Sinz
Todd Jonathan August Ewing
Victoria Anne Assimon
David John Morgans Jr
Maarten Hoek
Chris Ziebenhaus
Alexander Wayne Schammel
Adam Neil Reid
Birong Zhang
Sarah M Bronner
Original Assignee
Maze Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maze Therapeutics Inc filed Critical Maze Therapeutics Inc
Priority claimed from PCT/US2023/060787 external-priority patent/WO2023141432A2/en
Publication of CR20240344A publication Critical patent/CR20240344A/es

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En este documento se proporcionan compuestos de fórmula (II): <img src="data:image/png;base64,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 (***)
CR20240344A 2022-01-18 2023-01-17 Inhibidores de apol1 y métodos de uso CR20240344A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263300592P 2022-01-18 2022-01-18
US202263311668P 2022-02-18 2022-02-18
US202263332553P 2022-04-19 2022-04-19
US202263400359P 2022-08-23 2022-08-23
US202263442341P 2022-11-03 2022-11-03
PCT/US2023/060787 WO2023141432A2 (en) 2022-01-18 2023-01-17 Apol1 inhibitors and methods of use

Publications (1)

Publication Number Publication Date
CR20240344A true CR20240344A (es) 2024-12-09

Family

ID=94538390

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240344A CR20240344A (es) 2022-01-18 2023-01-17 Inhibidores de apol1 y métodos de uso

Country Status (1)

Country Link
CR (1) CR20240344A (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4465982A4 (en) * 2022-01-18 2025-11-26 Maze Therapeutics Inc APOL1 INHIBITORS AND METHODS OF USE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4465982A4 (en) * 2022-01-18 2025-11-26 Maze Therapeutics Inc APOL1 INHIBITORS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
Pestrak et al. Treatment with the Pseudomonas aeruginosa glycoside hydrolase PslG combats wound infection by improving antibiotic efficacy and host innate immune activity
Li et al. Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: A possible role for HDAC2 activity
NO20053114L (no) Astma og allergisk inflammasjonsmodulatorer.
MX2022006033A (es) Lipidos ionizables y composiciones de nanoparticulas de estos.
Lai et al. Histones of neutrophil extracellular traps directly disrupt the permeability and integrity of the intestinal epithelial barrier
HRP20050416A2 (en) Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
Wang et al. Pharmacological dual inhibition of tumor and tumor-induced functional limitations in a transgenic model of breast cancer
TN2010000284A1 (fr) Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP4473968A3 (en) Pyridazinone compounds and uses thereof
WO2023154807A3 (en) Compositions and methods for modulating pre-mrna splicing
Parasaram et al. Pentagalloyl glucose increases elastin deposition, decreases reactive oxygen species and matrix metalloproteinase activity in pulmonary fibroblasts under inflammatory conditions
Refsnes et al. Concentration‐dependent cytokine responses of silica nanoparticles and role of ROS in human lung epithelial cells
MA54903A (fr) Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1
MX2021007738A (es) Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer.
AU2021413753A9 (en) Compositions and methods for delivery of rna
ATE498022T1 (de) Universelle vervielfältigung von fragmentierter rns
MX2024005658A (es) Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
MX2025015719A (es) Composiciones y métodos para usar conjugados de anticuerpo-oligonucleótido de direccionamiento a pln
Chen et al. ERK1 loss accelerates the progression of osteoarthritis in aged mice via NRF2/BACH1 signaling
Wang et al. VPA enhances pulp regeneration by regulating LPS-induced human dental pulp stem cells odontogenic differentiation
MA65143A1 (fr) Compositions d&#39;inhibiteur de transporteur dépendant du sodium apical
JP6004499B2 (ja) クロマチン構造を制御する組成物
Wongsuwanlert et al. Effect of mouthwash containing poly L-Lysine and glycerol monolaurate on oral Helicobacter pylori relating to biofilm eradication, anti-adhesion, and pro-inflammatory cytokine suppression
CA3263050A1 (en) Compositions for targeted lysosomal degradation and their methods of use
WO2022098989A1 (en) Modulation of gene expression via transcription factor-chemically induced proximity (tf-cip)